Fortress Biotech subsidiary Journey Medical receives FDA approval for Emrosi to treat rosacea in adults

Fortress Biotech, Inc.

FDA approved Emrosi (Minocycline HCL ER 40mg) for inflammatory lesions of rosacea; Journey Medical to market it in U.S.
Phase 3 trials met all endpoints; Emrosi showed statistically significant superiority over Oracea® 40mg and placebo.
Initial supply expected late Q1 or early Q2 2025; developed with Dr. Reddy’s Laboratories.
Journey Medical is a majority-controlled subsidiary of Fortress Biotech (FBIO).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.